¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀå
Microarray Scanners
»óǰÄÚµå : 1775013
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 385 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ¼¼°è ½ÃÀåÀº 2030³â±îÁö 14¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9¾ï 8,610¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çü±¤ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê´Â ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß Çϳª·Î CAGRÀº 5.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 4,340¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀüÇϰáÇÕ¼ÒÀÚ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 8.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 6,870¸¸ ´Þ·¯, Áß±¹Àº CAGR 10.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀåÀº 2024³â¿¡ 2¾ï 6,870¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 10.0%¸¦ ±â·ÏÇϸç 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 2¾ï 9,300¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.3%¿Í 6.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³´×ÀÇ ±â¼úÀû ¸£³×»ó½º ¿øµ¿·ÂÀº?

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀåÀº ¹ÙÀÌ¿À¸ÞµðÄà ±â¼ú°ú À¯ÀüüÇÐÀÇ »õ·Î¿î ¹ßÀüÀÌ ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ À¯¿ë¼º°ú È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ ¼ö·ÅÇÔ¿¡ µû¶ó Å« º¯È­¸¦ °Þ°í ÀÖ½À´Ï´Ù. DNA, RNA, ´Ü¹éÁú ¾î·¹ÀÌÀÇ Çü±¤ ½ÅÈ£¸¦ °ËÃâÇϰí Á¤·®È­ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê´Â Çö´ë ºÐÀÚÁø´ÜÇÐÀÇ ÇÙ½É ¿ä¼Ò·Î, ¿¬±¸ÀÚµéÀº ÇÑ ¹øÀÇ ½ÇÇèÀ¸·Î ¼öõ °³ÀÇ À¯Àü ¹°ÁúÀ» ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Á¦¾àȸ»ç ¹× ¿¬±¸¼Ò´Â ÀÌ·¯ÇÑ ½ºÄ³³Ê¸¦ Ȱ¿ëÇÏ¿© ´ë±Ô¸ð À¯ÀüÀÚ ¹ßÇö ÇÁ·ÎÆÄÀϸµ, À¯ÀüÇüÁú ºÐ¼®, ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀ» ¼öÇàÇϰí ÀÖ½À´Ï´Ù. °íÇØ»óµµ ½ºÄ³³Ê´Â S/Nºñ Çâ»ó, ¸ÖƼÇ÷º½Ì ±â´É, ½ºÄµ ½Ã°£ ´ÜÃà µî ±â¼úÀû ÁøÈ­·Î ±× ÇѰ迡 µµÀüÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ´Â µÎµå·¯Áø Æ®·»µå Áß Çϳª´Â ½ºÄ³³Ê ¼ÒÇÁÆ®¿þ¾î¿¡ AI¿Í ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© º¹ÀâÇÑ »ý¹°ÇÐÀû µ¥ÀÌÅ͸¦ º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô ÇØ¼®ÇÒ ¼ö ÀÖµµ·Ï ½Ç½Ã°£ ºÐ¼®°ú ÆÐÅÏ ÀÎ½Ä ±â´ÉÀ» °­È­ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â´ÉÀÇ µµÀÔÀº ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÌ ¾Ï ƯÀÌÀû µ¹¿¬º¯ÀÌ È®ÀÎ ¹× Ä¡·á È¿°ú ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀÎ Á¾¾çÇÐ °°Àº ºÐ¾ß¿¡¼­ ƯÈ÷ À¯¿ëÇÏ°Ô È°¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ·¹´õº£½º Çü±¤ ½Ã½ºÅÛ, °øÃÊÁ¡ ½ºÄ³´× ±â¼ú µî ±¤ÇÐ Çõ½ÅÀ» ÅëÇØ °¨µµ¿Í ÇØ»óµµ°¡ Çâ»óµÇ¾î ¿¬±¸ÀÚµéÀº ÀûÀº ¾çÀÇ À¯Àü ¹°Áúµµ °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ¿¬±¸ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ºÐÀÚÁø´ÜÇÐÀÇ ¿À·£ °úÁ¦ÀÎ ½ÇÇèÀÇ º¯µ¿¼º À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¿¬±¸ ¾ÖÇø®ÄÉÀ̼ÇÀº ½ºÄ³³ÊÀÇ ¼º´É¿¡ °É¸Â°Ô ºü¸£°Ô ÁøÈ­Çϰí Àִ°¡?

»ý¹°ÇÐ ¹× Á¦¾à ¿¬±¸ ¿ªÇÐÀÇ º¯È­´Â ½ÃÀå ¿ªÇÐ ½ÃÀå Çü¼º¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Çмú ¹× »ó¾÷ ¿¬±¸ ±â°üÀÌ À¯ÀüüÇлӸ¸ ¾Æ´Ï¶ó Àü»çüÇÐ, ´Ü¹éÁúüÇÐ, ÈÄ»ýÀ¯ÀüÇÐ µîÀÇ ºÐ¾ß·Î ¿µ¿ªÀ» È®ÀåÇÔ¿¡ µû¶ó ´ÙÀç´Ù´ÉÇÏ°í °íµµ·Î ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ´Â ½ºÄ³´× Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê´Â ȯ°æ ¸ð´ÏÅ͸µ, ³ó¾÷À¯ÀüüÇÐ, °¨¿°º´ °¨½Ã µî º¸´Ù ±¤¹üÀ§ÇÑ ¾ÖÇø®ÄÉÀ̼ǿ¡ ÃÖÀûÈ­µÇ°í ÀÖÀ¸¸ç, À¯Àüü ¿¬±¸¿¡¸¸ ±¹ÇѵǾú´ø ±âÁ¸ÀÇ ¿ªÇÒ¿¡¼­ ¹þ¾î³ª°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÀ¿ë ¹üÀ§ÀÇ È®´ë´Â ƯÈ÷ ³ó¾÷ »ý¸í°øÇÐ ºÐ¾ß¿¡¼­ µÎµå·¯Áö¸ç, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µ¥ÀÌÅÍ´Â À¯ÀüÀÚ ¹ßÇö ¿¬±¸, ½ºÆ®·¹½º ¹ÝÀÀ ºÐ¼®, º´¿øÃ¼ ³»¼º ÇÁ·ÎÆÄÀϸµÀ» ÅëÇØ ÀÛ¹° °³·®¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, º¹ÀâÇÏ°í ´ÙÃþÀûÀÎ »ý¹°ÇÐÀû Áú¹®ÀÇ Áõ°¡´Â ´ÙÁß ºÐ¼® ±â¹ýÀÇ Áõ°¡¿¡ ´ëÀÀÇÏ¿© ½ºÄ³³Ê Á¦Á¶¾÷ü´Â ´Ù¾çÇÑ ¾î·¹ÀÌ ±¸¼º¿¡ ´ëÇØ ÀϰüµÈ ͏®ºê·¹ÀÌ¼Ç ¹× À̹Ì¡ ¼º´ÉÀ¸·Î ´Ù¾çÇÑ ¾î·¹ÀÌ ±¸¼ºÀ» Áö¿øÇÒ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» °³¹ßÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ-±â¾÷°ú Çаè¿ÍÀÇ °øµ¿ ÇÁ·ÎÁ§Æ®´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ Àû¿ëÀ» ´õ¿í È®´ëÇÏ¿© ÇØ¾ç»ý¹°ÇÐ, ½Å°æÀ¯ÀüÇÐ, Áٱ⼼Æ÷ ¿¬±¸¿Í °°Àº ƯÁ¤ ºÐ¾ß¿¡ ¸Â´Â Æ´»õ Á¦Ç° ¼³°è¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¿À´Ã³¯ÀÇ ½ºÄ³³Ê Ç÷§ÆûÀº Á¡Á¡ ´õ ¸¹Àº ¾ÖÇø®ÄÉÀÌ¼Ç ¿µ¿ª»Ó¸¸ ¾Æ´Ï¶ó °¢°¢ÀÇ °íÀ¯ÇÑ µ¥ÀÌÅÍ Çü½Ä°ú ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©µµ Áö¿øÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¾ß °£ ¼ö¿ä´Â »óÈ£¿î¿ë¼ºÀÇ Á߿伺À» È¿°úÀûÀ¸·Î ³ôÀ̰í, ´ë±Ô¸ð µ¥ÀÌÅÍ °øÀ¯ ¹× °øµ¿ ºÐ¼®À» ¿ëÀÌÇÏ°Ô ÇÏ´Â ¿ÀÇ ¼Ò½º µ¥ÀÌÅÍ Ã³¸® µµ±¸¿Í Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀÇ ÅëÇÕÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®Àº ½ÃÀåÀÇ ¹æÇ⼺°ú ÅõÀÚ¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

Áø´Ü ¿¬±¸¼Ò, Á¦¾àȸ»ç, ¿¬±¸±â°ü µî °¢±â °íÀ¯ÇÑ ´ÏÁ °¡Áö°í Á¦Ç° °³¹ßÀÇ Àü¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× Áúº´ Á¶±â ¹ß°ßÀÇ Ãß¼¼¿¡ ÈûÀÔ¾î, Áø´Ü ½ÇÇè½Ç¿¡¼­´Â ȯÀÚ »ùÇÃÀÇ ½Å¼ÓÇÑ ½ºÅ©¸®´× ¹× ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» À§ÇØ ÇÏÀ̽º·çDz ½ºÄ³³Ê¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­, ÃÖ¼ÒÇÑÀÇ »ùÇà Á¶Á¦, ³ôÀº ½Å·Ú¼ºÀ» ¼±È£Çϱ⠶§¹®¿¡ ½ºÄ³³Ê °³¹ßÀÚµéÀº Á÷°üÀûÀÎ »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º¿Í ÃÖ¼ÒÇÑÀÇ À¯Áöº¸¼ö ¿ä°ÇÀ» °®Ãá Ç÷¯±× ¾Ø Ç÷¹ÀÌ ½Ã½ºÅÛ¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÇÑÆí, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷µéÀº ƯÈ÷ ÁÖ¿ä ¸®µå ¹ß±¼ ¹× °ËÁõ ´Ü°è¿¡¼­ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê¸¦ ½Å¾à°³¹ß ÆÄÀÌÇÁ¶óÀο¡ ÅëÇÕÇÏ¿© ³ôÀº ¼öÁØÀÇ ½ºÅ©¸®´× ¿ª·®À» °­È­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

º´¿ø°ú ÀÓ»ó ¿¬±¸ ±â°üµéµµ ȯÀÚ °èÃþÈ­ ¹× Ä¡·á ÃÖÀûÈ­¸¦ À§ÇØ À¯Àüü ºÐ¼®¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖÀ¸¸ç, ½ÃÀå È®´ëÀÇ °­·ÂÇÑ ±â¿©ÀÚ·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ, ƯÈ÷ ¾Ï, ½ÉÇ÷°üÁúȯ, ½Å°æÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»ó ÇöÀå¿¡¼­´Â ±âÁ¸ Áø´Ü ÅøÀ» º¸¿ÏÇϱâ À§ÇØ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Áø´Ü¿ë ¿öÅ©Ç÷ο츦 äÅÃÇÏ´Â »ç·Ê°¡ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ ÀÚ±Ý Áö¿øÀº ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ±âÁ¸ ¿¬±¸¼Ò¿Í ½Å»ý ±â¾÷ ¸ðµÎ ÃֽнºÄ³´× Àåºñ¿¡ ÅõÀÚÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ´Ù¾çÇÑ °í°´ÃþÀ» âÃâÇϰí, Á¦Á¶¾÷üµéÀÌ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ ´Ù¾çÈ­ÇÏ¿© ´Ù¾çÇÑ ¼ö¿ä¿Í ¿¹»ê ¿ä±¸»çÇ׿¡ ¸Â´Â ´Ü°èº° ¼Ö·ç¼ÇÀ» Á¦°øÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀå ¼ºÀå °¡¼ÓÈ­ ¿äÀÎÀº?

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, ÁøÈ­ÇÏ´Â ÃÖÁ¾»ç¿ëÀÚ ´ÏÁî, ´Ù¾çÇÑ »ê¾÷¿¡¼­ À¯ÀüüÇÐÀÇ Á߿伺 Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀûÀ¸·Î´Â ´õ ºü¸¥ ¼Óµµ, ³ôÀº Á¤È®µµ, µ¥ÀÌÅÍ ºÐ¼® Ç÷§Æû°úÀÇ ÅëÇÕÀ» Á¦°øÇÏ´Â °íÇØ»óµµ ÀÚµ¿ ½ºÄµ ½Ã½ºÅÛÀÇ µîÀåÀÌ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû µ¥ÀÌÅÍÀÇ ¾ç°ú º¹À⼺ÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ƯÈ÷ ´ë±Ô¸ð À¯ÀüüÇÐ ¹× ´Ü¹éÁúüÇÐ ¿¬±¸¿¡¼­ ½Ç½Ã°£ µ¥ÀÌÅÍ Ã³¸®¿Í È®Àå °¡´ÉÇÑ Ãâ·Â¿¡ ´ëÇÑ Áß¿äÇÑ ¿ä±¸¸¦ ÃæÁ·½Ã۰í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í Àӻ󿬱¸±â°üÀº ÀǾàǰ °³¹ß ¹× Áø´Ü ºÐ¼®ÀÇ °ËÁõÀ» Áö¿øÇÒ ¼ö ÀÖ´Â ¸ÖƼ ¾ÖÇø®ÄÉÀÌ¼Ç Ç÷§ÆûÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, Á¦Á¶»çµéÀº È®Àå °¡´ÉÇÏ°í ¸ðµâÈ­µÈ ¼Ö·ç¼ÇÀ» Á¦°øÇØ¾ß ÇÕ´Ï´Ù.

Çаè¿Í »ý¸í°úÇÐ ¿¬±¸ ºÐ¾ß¿¡¼­´Â ºÐÀÚ»ý¹°ÇÐ ¹× À¯Àüü ¿¬±¸¸¦ ´ë»óÀ¸·Î ÇÑ ÅõÀÚ ¹× Á¤ºÎ Áö¿øÀÇ Áõ°¡°¡ ƯÈ÷ ÀÇ·á ¿¬±¸°³¹ß ÀÎÇÁ¶ó°¡ ºü¸£°Ô ±¸ÃàµÇ°í ÀÖ´Â ½ÅÈï °æÁ¦±¹¿¡¼­ ½ºÄ³³Ê µµÀÔÀ» Á÷Á¢ÀûÀ¸·Î ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ÒºñÀÚ Á÷Á¢ À¯ÀüÀÚ °Ë»çÀÇ Áõ°¡¿Í ¸ÂÃãÇü ÇコÄɾîÀÇ ºÎ»óÀ¸·Î »ó¾÷Àû ȯ°æ¿¡¼­ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÌ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ º¯È­Çϰí ÀÖÀ¸¸ç, ´õ ¸¹Àº »ç¶÷µéÀÌ Á¾ÇÕÀûÀÎ À¯ÀüÇÐÀû ÀλçÀÌÆ®¸¦ ¿øÇϰí, ¼ÒºñÀÚµéÀÌ ¼ö¿ëÇÒ ¼ö ÀÖ´Â ³³±â ³»¿¡ Á¤È®ÇÏ°í ½Ç¿ëÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇÏ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê¸¦ äÅÃÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ó¾÷, ȯ°æ °úÇÐ, ¹ÙÀÌ¿À º¸¾È ºÐ¾ß¿¡¼­ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¼®ÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ Áö¿ªÀû, »ê¾÷Àû È®ÀåÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå ¿äÀÎÀº ½ÃÀå È®´ë¸¦ °¡¼ÓÈ­ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê°¡ °úÇÐ-»ó¾÷Àû »ýŰ迡 ÆíÀԵǴ °æ·Î¸¦ ´Ù¾çÈ­Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(Çü±¤ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê, ÀüÇϰáÇÕ¼ÒÀÚ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê, ºñ»ö ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê, ±âŸ Á¦Ç° À¯Çü), ¿ëµµ(À¯ÀüÀÚ ¹ßÇö ºÐ¼® ¿ëµµ, ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¿ëµµ, Drug Discovery ¿ëµµ, À¯ÀüÀÚÇü ÆÇÁ¤¡¤SNP ºÐ¼® ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤Å¬¸®´Ð ÃÖÁ¾ ¿ëµµ, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, Áø´Ü ¿¬±¸¼Ò ÃÖÁ¾ ¿ëµµ, Çмú¡¤¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Microarray Scanners Market to Reach US$1.4 Billion by 2030

The global market for Microarray Scanners estimated at US$986.1 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Fluorescence Microarray Scanners, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$643.4 Million by the end of the analysis period. Growth in the Charge Coupled Devices Microarray Scanners segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$268.7 Million While China is Forecast to Grow at 10.0% CAGR

The Microarray Scanners market in the U.S. is estimated at US$268.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$293.0 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Microarray Scanners Market - Key Trends & Drivers Summarized

What’s Powering the Technological Renaissance in Microarray Scanning?

The microarray scanners market is undergoing a significant transformation as new advancements in biomedical technology and genomics converge to enhance the utility and efficiency of these devices. Microarray scanners, which are used to detect and quantify fluorescent signals in DNA, RNA, or protein arrays, have become a core element in modern molecular diagnostics, enabling researchers to analyze thousands of genetic materials in a single experiment. With increasing emphasis on precision medicine, pharmaceutical companies and research laboratories are leveraging these scanners to conduct large-scale gene expression profiling, genotyping, and biomarker discovery. Technological evolution has also pushed the envelope with high-resolution scanners offering improved signal-to-noise ratios, multiplexing capabilities, and faster scanning times, which collectively help process more data in shorter durations with enhanced accuracy.

One notable trend driving innovation is the integration of AI and machine learning into scanner software, enabling real-time analytics and enhanced pattern recognition that assist in faster and more accurate interpretation of complex biological data. The deployment of these advanced features is particularly useful in fields like oncology, where microarray technology is critical for identifying cancer-specific mutations and monitoring treatment efficacy. In addition, optical innovations-such as the adoption of laser-based fluorescence systems and confocal scanning technologies-are improving sensitivity and resolution, allowing researchers to detect even low-abundance genetic material. These developments not only streamline research workflows but also reduce the risk of experimental variability, which is a long-standing challenge in molecular diagnostics.

Are Research Applications Evolving Fast Enough to Match Scanner Capabilities?

The shifting dynamics of biological and pharmaceutical research are playing a pivotal role in shaping the microarray scanners market. As academic and commercial research institutions expand their focus beyond genomics to areas like transcriptomics, proteomics, and epigenetics, the demand for versatile and highly customizable scanning platforms has surged. Microarray scanners are increasingly being optimized for broader applications such as environmental monitoring, agricultural genomics, and infectious disease surveillance, reflecting a significant departure from their traditional role confined to genomic research alone. This broadened application base is especially visible in agricultural biotechnology, where microarray data is instrumental in crop improvement through gene expression studies, stress-response analysis, and pathogen resistance profiling.

Moreover, the rise in complex, multi-layered biological questions has led to a corresponding increase in multiplex assay formats, pushing scanner manufacturers to develop systems capable of handling diverse array configurations with seamless calibration and imaging performance. Collaborative projects between biotech firms and academic institutions are further expanding microarray applications, encouraging the design of niche products tailored to specific fields like marine biology, neurogenetics, and stem cell research. As a result, scanner platforms today must cater not only to a growing number of application domains but also to the unique data formats and analytical frameworks that come with each. This cross-disciplinary demand has effectively elevated the importance of interoperability, leading to the integration of open-source data processing tools and cloud-based platforms that facilitate large-scale data sharing and collaborative analysis.

How Are End-Use Sectors Shaping Market Direction and Investment?

In terms of end-use, the microarray scanners market is experiencing significant momentum across diagnostic laboratories, pharmaceutical companies, and research institutes-each presenting unique needs that are reshaping the product development landscape. Diagnostic labs, driven by the growing trend of personalized medicine and early disease detection, are increasingly turning to high-throughput scanners for rapid screening and molecular profiling of patient samples. Their preference for automation, minimal sample preparation, and high reliability is prompting scanner developers to focus on plug-and-play systems with intuitive user interfaces and minimal maintenance requirements. Meanwhile, pharmaceutical and biotech companies are integrating microarray scanners into their drug discovery pipelines, particularly during lead identification and validation phases, to enhance their high-throughput screening capabilities.

Hospitals and clinical research organizations are also emerging as strong contributors to market expansion due to their rising dependence on genomic assays for patient stratification and therapy optimization. With the global rise of chronic diseases, particularly cancer, cardiovascular disorders, and neurological conditions, clinical settings are increasingly adopting microarray-based diagnostic workflows to supplement traditional diagnostic tools. Additionally, governmental and non-governmental funding for life sciences research is steadily increasing, which is encouraging both established labs and start-ups to invest in modern scanning equipment. These shifts are creating a diverse customer base, prompting manufacturers to diversify their product portfolios and offer tiered solutions that cater to varying throughput and budgetary requirements.

What’s Fueling the Accelerated Growth of the Microarray Scanners Market?

The growth in the microarray scanners market is driven by several factors that stem directly from technological innovation, evolving end-user needs, and the growing importance of genomics in diverse industries. Technologically, the advent of high-resolution and automated scanning systems that offer greater speed, precision, and integration with data analysis platforms is playing a key role. As the volume and complexity of biological data continue to increase, these systems are addressing a critical need for real-time data processing and scalable output, especially in large-scale genomics and proteomics studies. On the end-user front, pharmaceutical firms and clinical research organizations are demanding multi-application platforms capable of supporting drug development and diagnostic assay validation, pushing manufacturers to provide scalable and modular solutions.

In academia and life sciences research, rising investments and government funding initiatives targeting molecular biology and genomic studies are directly boosting scanner adoption, particularly in emerging economies where healthcare R&D infrastructure is being rapidly developed. Additionally, the growth in direct-to-consumer genetic testing and the rise of personalized healthcare are creating new avenues for microarray technologies in commercial settings. Consumer behavior is also shifting as more individuals seek comprehensive genetic insights, encouraging companies to adopt microarray scanners that deliver accurate and actionable data at consumer-acceptable turnaround times. Furthermore, the increasing application of microarray analysis in agriculture, environmental sciences, and biosecurity is expanding the market’s geographical and industrial reach. Collectively, these growth drivers are not just accelerating market expansion but also diversifying the pathways through which microarray scanners are integrated into scientific and commercial ecosystems.

SCOPE OF STUDY:

The report analyzes the Microarray Scanners market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Fluorescence Microarray Scanners, Charge Coupled Devices Microarray Scanners, Colorimetric Microarray Scanners, Other Product Types); Application (Gene Expression Analysis Application, Protein Microarrays Application, Drug Discovery Application, Genotyping & SNP Analysis Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â